Media Release
Race appoints Dr Daniel Tillett Chief Scientific Officer
Race Oncology is pleased to announce that Dr Daniel Tillett has been appointed Chief Scientific Officer (CSO) of RAC effective from 30 September 2019.
- Posted by: Race Oncology
FeaturedMedia Release
Race reveals new strategy for cancer drug Bisantrene
Race Oncology has revealed its new “5 Path” clinical development strategy for its cancer drug, Bisantrene.
- Posted by: Race Oncology
FeaturedMedia Release
Dr Daniel Tillett joins Race Board
Prominent biotechnology investor and substantial Race shareholder, Dr Daniel Tillett, has joined the Board of Directors of Race Oncology Ltd.
- Posted by: Race Oncology
FeaturedMedia Release
Prominent biotech investor leads investment in Race
Race Oncology Limited is pleased to announce the successful completion of a $1.45 million placement, led by prominent biotechnology investor Dr Daniel Tillett.
- Posted by: Race Oncology
FeaturedMedia Release
Race announces additional US Patent for Bisantrene
Race Oncology has announced it has secured a new patent on its cancer drug, Bisantrene, from the United States Patent and Trademarks Office (USPTO).
- Posted by: Race Oncology
FeaturedMedia Release
Race’s Israel trial treats first patient with Bisantrene
Race Oncology is pleased to announce the first patient has been treated with Bisantrene in the trial at the Sheba Medical Center in Israel, without any major complications.
- Posted by: Race Oncology
Media Release
Bisantrene investigator-initiated AML trial to start in Israel
Race Oncology has announced that it has signed an agreement to conduct a trial of Race's cancer drug, Bisantrene, at the Sheba Medical Center in Israel.
- Posted by: Race Oncology